Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis Academic Article uri icon

Overview

MeSH Major

  • Amyloidosis
  • Melphalan

abstract

  • Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete response (CR) rates and may improve overall survival (OS) for patients with

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5220129

Digital Object Identifier (DOI)

  • 10.1038/leu.2016.229

PubMed ID

  • 27560108

Additional Document Info

start page

  • 136

end page

  • 142

volume

  • 31

number

  • 1